Drug Trial Radar · NCT06294288
A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jul 13, 2022
Primary completion
Mar 4, 2024
Study completion Mar 4, 2024
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).
Conditions
- Chronic Spontaneous Urticaria
Interventions
LP-003 Dose 1 (Single)Biological
A single dose of LP-003 (Dose 1) was administered intravenously.
LP-003 Dose 2 (Single)Biological
A single dose of LP-003 (Dose 2) was administered intravenously.
LP-003 Dose 3 (Single)Biological
A single dose of LP-003 (Dose 3) was administered intravenously.
LP-003 Dose 4 (Single)Biological
A single dose of LP-003 (Dose 4) was administered intravenously.
LP-003 Dose 5 (Single)Biological
A single dose of LP-003 (Dose 5) was administered intravenously.
Placebo (Single)Biological
A single dose of placebo was administered intravenously.
LP-003 Dose 6 (Multiple)Biological
LP-003 (Dose 6) was administered multiple times subcutaneously.
LP-003 Dose 7 (Multiple)Biological
LP-003 (Dose 7) was administered multiple times subcutaneously.
LP-003 Dose 8 (Multiple)Biological
LP-003 (Dose 8) was administered multiple times subcutaneously.
Placebo (Multiple)Biological
Placebo was administered multiple times subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Observation for 280 days after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.